Startseite>>Isotope-Labeled Compounds>> Deuterium>>10-PAHSA-d31

10-PAHSA-d31

Katalog-Nr.GC46405

A neuropeptide with diverse biological activities

Products are for research use only. Not for human use. We do not sell to patients.

10-PAHSA-d31 Chemische Struktur

Cas No.: 2748489-85-0

Größe Preis Lagerbestand Menge
100 μg
111,00 $
Auf Lager
250 μg
250,00 $
Auf Lager
500 μg
445,00 $
Auf Lager
1 mg
780,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

10-PAHSA-d31 contains 31 deuterium atoms and is intended for use as an internal standard for the quantification of 10-PAHSA by GC- or LC-MS. 10-PAHSA is a newly identified endogenous lipid that belongs to a collection of branched fatty acid esters of hydroxy fatty acids (FAHFAs). 10-PAHSA is a FAHFA in which palmitic acid is esterified to 10-hydroxy stearic acid. Among the FAHFA family members, PAHSAs are the most abundant in the adipose tissue of glucose tolerant AG4OX mice, which overexpress the Glut4 glucose transporter specifically in adipose tissue.1 As other FAHFAs improve glucose tolerance, stimulate insulin secretion, and have anti-inflammatory effects, 10-PAHSA may be a bioactive lipid with roles in metabolic syndrome and inflammation.

1.Yore, M.M., Syed, I., Moraes-Vieira, P.M., et al.Discovery of a class of endogenous mammalian lipids with anti-diabetic and anti-inflammatory effectsCell.159(2)318-332(2014)

Bewertungen

Review for 10-PAHSA-d31

Average Rating: 5 ★★★★★ (Based on Reviews and 27 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 10-PAHSA-d31

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.